Author(s): Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR,
Abstract Share this page
Abstract Despite advances in the management of myeloablative allogeneic hematopoietic stem cell transplants, airflow obstruction (AFO) remains a significant complication. We conducted a 12-year study to examine the recent epidemiology of AFO and its associated mortality. Using the rate of percent predicted FEV1 decline after transplant, we defined AFO as a more than 5\% per year decline in percent predicted FEV1 with the lowest post-transplant FEV1/FVC ratio less than 0.8. New obstruction was more frequent than previous estimates (26\% overall, 32\% among patients with chronic graft-versus-host disease [GVHD]) and was significantly associated with older age at transplant, lower pretransplant FEV1/FVC ratio, history of both acute and chronic GVHD, and respiratory viral infection within the first 100 days after transplant. AFO was associated with significant attributable mortality rates of 9\% at 3 years, 12\% at 5 years, and 18\% at 10 years after transplant, which were much higher for the subpopulation of patients with chronic GVHD (22\% at 3 years, 27\% at 5 years, and 40\% at 10 years). These results suggest that the incidence of AFO may have been underestimated previously, and its presence significantly increases the mortality of long-term survivors of myeloablative allogeneic hematopoietic stem cell transplant patients.
This article was published in Am J Respir Crit Care Med
and referenced in Journal of Clinical and Experimental Transplantation